vaccin
remain
success
effect
mechan
pathogen
control
howev
develop
deploy
epidem
set
limit
ebola
outbreak
west
africa
identifi
sever
bottleneck
link
lack
invest
pathogen
research
infrastructur
regul
shortli
outbreak
uk
govern
establish
uk
vaccin
network
ensur
uk
better
prepar
respond
pathogen
outbreak
epidem
potenti
part
work
network
commiss
creation
vaccin
develop
tool
http
wwwvaccinedevelopmentorguk
serv
guid
key
stage
vaccin
develop
tool
also
set
captur
key
ratelimit
bottleneck
develop
vaccin
emerg
infecti
diseas
correct
action
could
taken
research
fund
infrastructur
polici
uk
intern
main
research
bottleneck
relat
understand
pathogen
biolog
identif
appropri
anim
model
invest
manufactur
scienc
especi
process
develop
infrastructur
gap
gmp
manufactur
fillfinish
also
identifi
limit
gmo
regul
regulatori
ethic
approv
especi
outbreak
pathogen
requir
new
polici
initi
uk
vaccin
network
sinc
begun
work
correct
limit
seri
fund
call
develop
programm
paper
seek
summaris
vaccin
develop
tool
key
find
time
respons
epidem
requir
develop
manufactur
distribut
vaccin
activ
uk
vaccin
network
ukvn
seen
identif
sever
pathogen
epidem
potenti
howev
develop
effect
vaccin
pathogen
requir
improv
coordin
polici
maker
funder
research
vaccin
manufactur
regul
develop
deploy
vaccin
mitig
spread
epior
pandem
set
context
ebola
outbreak
began
multipl
stakehold
mobilis
respond
humanitarian
crisi
escal
outbreak
although
licenc
ebola
vaccin
avail
approxim
fifteen
differ
vaccin
preclin
develop
includ
dna
vaccin
viruslik
particl
viral
vector
levin
et
al
describ
candid
larg
develop
part
bioterror
prepared
programm
bioshield
unit
state
due
rel
low
geograph
preval
infect
limit
market
thu
poor
case
industri
develop
vaccin
commerci
purpos
howev
concern
potenti
use
ebolaviru
bioterror
agent
result
number
stockpil
sourc
undergon
test
anim
model
ebola
epidem
worsen
avail
small
vaccin
stockpil
taken
togeth
threat
spread
catalys
stakehold
engag
test
vaccin
human
determin
safeti
potenti
deploy
research
industrialist
regul
funder
work
togeth
expedit
process
carri
firstinman
trial
ebola
vaccin
email
address
siobhanjolliff
homeofficegovuk
jolliff
ucbetkm
ucl
acuk
tk
mukhopadhyay
unpreced
intern
consortium
assembl
acceler
collabor
multisit
trial
candid
ebola
vaccin
wellcom
trust
august
http
wellcomeacukpressreleaseunprecedentedinternationalconsortiumassembledacceleratecollaborativemultisit
last
access
august
vaccin
content
list
avail
sciencedirect
vaccin
j
u
r
n
l
h
e
p
g
e
w
w
w
e
l
e
v
e
r
c
l
c
e
v
c
c
n
e
vaccin
deploy
part
intern
respons
although
outbreak
also
serv
highlight
necess
effect
public
health
system
infrastructur
commun
engag
order
mitig
diseas
spread
cultur
social
practic
case
ebola
fortuit
sever
candid
vaccin
alreadi
develop
immens
global
effort
made
vaccin
avail
howev
also
conspicu
highlight
nation
around
world
need
better
prepar
outbreak
infecti
diseas
particularli
potenti
high
level
morbid
mortal
measur
control
infect
spread
also
implement
unit
kingdom
uk
strong
intern
reput
scientif
research
innov
long
histori
vaccinolog
along
countri
uk
govern
mobilis
resourc
manag
ebola
outbreak
well
play
role
test
ebola
vaccin
uk
west
africa
alongsid
effort
uk
chief
medic
offic
depart
health
social
care
dhsc
dame
salli
davi
rais
question
govern
relat
stakehold
could
uk
better
prepar
futur
outbreak
infecti
diseas
partnership
instig
across
dhsc
uk
medic
research
council
mrc
biotechnolog
biolog
scienc
research
council
bbsrc
work
togeth
establish
uk
vaccin
network
ukvn
wwwgovukgovernmentgroup
ukvaccinesnetwork
bring
togeth
small
number
specialist
industri
academia
relev
fund
bodi
make
target
invest
specif
vaccin
vaccin
technolog
infecti
diseas
potenti
caus
epidem
inaugur
meet
juli
ukvn
discuss
potenti
prioriti
area
invest
member
agre
four
work
group
wg
follow
foci
prioritis
pathogen
like
caus
epidem
pandem
short
medium
term
rationalis
vaccin
develop
resourc
prioritis
intervent
possibl
understand
challeng
vaccin
develop
key
rate
limit
step
given
vaccin
develop
address
manufactur
capac
vaccin
paper
describ
activ
undertaken
work
group
vaccin
develop
group
creat
visual
process
map
tool
better
understand
potenti
ratelimit
bottleneck
associ
move
vaccin
candid
discoveri
develop
earli
phase
clinic
trial
clinic
manufactur
phase
trial
primari
purpos
tool
act
visual
aid
earli
discoveri
develop
scientist
highlight
major
step
requir
fulli
develop
experiment
vaccin
secondari
crucial
purpos
tool
identifi
gener
bottleneck
may
slow
develop
identifi
strateg
limit
may
identifi
correct
action
may
turn
help
overcom
potenti
delay
setback
expedit
vaccin
develop
epidem
action
could
taken
polici
maker
correct
limit
regul
funder
identifi
limit
scientif
knowledg
could
correct
appropri
invest
govern
transnat
organis
consid
local
global
respons
though
genesi
tool
consid
context
epidem
prepared
tool
suffici
farreach
util
wider
vaccin
commun
consid
global
natur
vaccin
import
understand
interdepend
exist
discoveri
develop
manufactur
tool
give
scientist
vision
consider
need
made
along
develop
process
take
much
holist
approach
vaccin
develop
hope
support
intern
global
vaccin
action
plan
reli
continu
suppli
vaccin
meet
immun
target
thu
tool
serv
multipl
user
purpos
report
main
find
paper
initi
literatur
consult
basic
schemat
overview
major
step
creat
fell
four
main
area
preclin
discoveri
ii
preclin
develop
iii
manufactur
iv
clinic
trial
sever
subgroup
conven
discuss
area
membership
drawn
ukvn
core
group
specialist
made
expertis
consult
accord
need
process
schemat
made
member
undertook
interact
discuss
add
remov
reorganis
step
ukvn
secretariat
led
organis
seri
iter
workshop
repeat
process
sever
time
time
skill
gap
analysi
carri
ensur
appropri
expertis
repres
differ
diseasevaccin
interest
across
vaccin
sector
academ
industri
discoveri
develop
regul
manufactur
clinic
trial
repeat
process
interact
map
refin
core
document
present
progress
back
subgroup
stimul
dialogu
map
whole
concert
effort
break
silo
disciplin
sector
address
choic
made
earli
discoveri
may
affect
later
develop
pathway
iter
interact
work
subgroup
met
agre
final
node
bottleneck
map
final
figur
transcrib
powerpoint
imag
use
basi
interact
webpag
construct
mrc
regulatori
support
centr
mrc
rsc
http
mrcukriorgresearchfacilitiesandresourcesforresearchersregulatorysupportcentr
mrc
rsc
offer
design
main
menu
layout
colour
scheme
agre
secretariat
graphic
tool
drawn
use
adob
illustr
save
webfriendli
format
websit
built
dreamweav
use
code
effort
made
make
site
respons
differ
devic
possibl
text
possibl
map
due
complex
subject
final
version
seen
wwwvaccinedevelopmentorguk
process
map
workshop
culmin
product
websit
standalon
page
map
distinguish
follow
major
subdivis
target
product
profil
tpp
preclin
discoveri
preclin
develop
clinic
develop
regulatori
affair
ethic
approv
fig
due
mandat
remit
tool
use
ukvn
develop
vaccin
outbreak
agre
tool
need
address
step
market
access
authoris
outbreak
vaccin
would
normal
undergo
process
instead
deploy
small
popul
accord
need
necessari
evid
safeti
immunogen
achiev
target
product
profil
tpp
descript
document
set
clear
paramet
characterist
desir
end
product
intend
use
market
design
entri
point
process
map
came
repetit
discuss
prevail
import
tpp
stage
develop
simpl
term
know
make
agre
signific
tpp
relev
even
earliest
exploratori
basic
scienc
work
underestim
therefor
promin
place
tpp
aim
engag
earli
discoveri
scientist
consid
end
product
choic
made
preclin
discoveri
develop
influenc
consensu
opinion
within
work
group
tpp
seen
strateg
plan
document
utilis
benchmark
data
emerg
normal
develop
tool
novel
vaccin
creation
howev
outbreak
situat
tpp
act
essenti
checklist
acceler
timescal
worth
note
import
tpp
wide
share
recent
work
cepi
includ
creat
standard
tpp
prioriti
pathogen
iter
workshop
host
ongo
discuss
involv
step
might
rate
limit
step
slow
develop
agreement
almost
anyth
could
describ
bottleneck
step
necessari
natur
discoveri
research
develop
endeavour
take
time
howev
order
scrutin
bottleneck
could
potenti
amelior
correct
action
invest
govern
research
funder
polici
maker
agre
tool
identifi
step
correct
action
could
taken
could
potenti
acceler
vaccin
develop
main
bottleneck
correct
action
requir
summaris
tabl
addit
import
consider
identif
bottleneck
node
suffici
gener
appli
rang
vaccin
type
pathogen
thu
refin
key
step
common
denomin
share
across
approach
overal
mani
bottleneck
focus
around
gap
fund
scientif
knowledg
train
infrastructur
addit
item
harmonis
regul
especi
regard
releas
genet
modifi
organ
gmo
bottleneck
readili
seen
process
map
click
show
bottleneck
map
page
describ
main
bottleneck
highlight
stage
within
preclin
discoveri
understand
pathogen
biolog
develop
appropri
anim
challeng
model
seen
signific
limit
factor
especi
emerg
infecti
diseas
abil
screen
test
verifi
potenti
new
antigen
critic
import
increas
research
fund
standardis
methodolog
vitro
vivo
test
work
humanlivestock
host
immunolog
would
critic
increas
capac
lead
candid
identifi
ensur
work
appropri
freedom
oper
becom
increasingli
import
review
intellectu
properti
landscap
includ
search
antigen
cell
line
biolog
method
employ
creat
requir
time
complet
could
littl
three
month
increas
complex
conduct
freedom
oper
review
import
step
toward
commercialis
yet
outbreak
scenario
special
regul
compulsori
licensur
stepin
right
may
allow
issu
sidestep
would
requir
clarif
polici
preclin
develop
complex
multistep
timeconsum
process
fig
requir
vaccin
candid
undergo
strain
develop
confirm
antigen
present
verifi
anim
studi
follow
process
develop
ensur
scalabl
robust
gmp
compliant
manufactur
process
creat
materi
gener
end
preclin
develop
use
anim
toxicolog
studi
form
basi
clinic
trial
applic
first
bottleneck
encount
strain
develop
develop
work
occur
use
research
cell
bank
howev
research
cell
bank
gener
gmp
standard
therefor
delay
later
stage
avoid
ensur
bank
gmp
compliant
often
requir
reclon
traceabl
cell
line
gmp
certifi
free
adventiti
agent
major
bottleneck
around
process
develop
creat
scalabl
gmp
compliant
manufactur
process
determin
critic
process
paramet
stage
manufactur
must
address
vaccin
fact
manufactur
scalabl
process
gener
manufactur
process
vaccin
thu
almost
process
design
bottom
add
cost
delay
futur
intervent
plan
platform
manufactur
technolog
method
overcom
issu
streamlin
manufactur
gener
oper
select
antigen
introduc
viral
vector
one
platform
technolog
effect
employ
ebola
outbreak
look
broadli
recombin
subunit
vaccin
technolog
anoth
platform
technolog
could
use
epidem
success
demonstr
context
influenza
vaccin
advanc
nucleic
acid
base
vaccin
dna
rna
offer
futur
though
yet
unrealis
potenti
gener
manufactur
releas
test
vaccin
determin
rang
physic
chemic
biolog
microbiolog
properti
ensur
qualiti
desir
product
describ
critic
qualiti
attribut
cqa
requir
welldefin
analyt
long
term
reduc
qualiti
control
qc
cost
find
suitabl
analyt
resolv
complex
antigen
structur
increas
understand
degrad
pathway
formul
need
continu
bottleneck
funder
must
ensur
process
develop
manufactur
analyt
overlook
futur
research
call
bottleneck
encount
anim
vivo
studi
characteris
immunogen
reactogenec
relev
anim
model
imper
take
forward
vaccin
candid
phase
model
potenti
bottleneck
associ
home
offic
approv
contain
level
facil
depend
pathogen
studi
suppli
anim
gmp
manufactur
infrastructur
bottleneck
requir
funder
polici
maker
examin
pressur
upon
current
manufactur
model
almost
vaccin
manufactur
oper
capac
dedic
product
singl
product
stepin
right
emerg
scenario
disrupt
suppli
essenti
vaccin
also
caus
delay
recruit
cmo
task
may
help
allevi
situat
essenti
train
knowhow
requir
furthermor
site
may
suitabl
certain
vaccin
class
rang
protein
subunit
vaccin
live
viral
bacteri
vaccin
base
vaccin
class
facil
may
appropri
contain
level
bulk
manufactur
drug
substanc
fillfinish
drug
product
inde
mani
facil
fillfinish
oper
coloc
fillfinish
also
bottleneck
clinic
develop
due
limit
number
appropri
site
volum
vial
requir
phase
trial
uk
govern
ukvn
provid
evid
advic
identifi
manufactur
infrastructur
signific
bottleneck
sought
invest
new
vaccin
develop
manufactur
centr
http
wwwgov
ukgovernmentnewsmedicineandvaccinemanufacturingcentresapplyforfund
organis
cepi
also
issu
call
propos
new
platform
manufactur
technolog
cepinet
situat
exist
statu
quo
may
vaccin
utilis
fight
futur
epidem
manufactur
capac
enabl
product
distribut
latest
call
seek
revers
current
limit
mani
prioriti
pathogen
prone
sporad
outbreak
due
potenti
lethal
possibl
conduct
full
phase
trial
even
phase
studi
may
prove
challeng
human
popul
due
unpredict
natur
outbreak
nonetheless
sequenti
clinic
trial
step
would
compris
normal
step
develop
vaccin
taken
forward
licensur
incorpor
tool
clinic
trial
requir
great
invest
resourc
execut
lengthi
natur
process
could
describ
bottleneck
purpos
tool
howev
highlight
five
step
within
clinic
develop
current
gmo
regul
distinguish
vaccin
base
viral
vector
live
replic
incompet
vector
base
bacteria
virus
current
regul
stipul
use
gmo
vaccin
done
contain
use
deliber
releas
protocol
prevent
releas
environ
consequ
may
involv
obtain
separ
approv
modif
trial
site
modifi
procedur
sterilis
administ
dispos
separ
storag
facil
special
train
staff
handl
gmo
overal
whole
area
would
benefit
revis
regul
derog
use
common
vaccin
vector
separ
regul
current
applic
gmo
guidanc
would
substanti
benefici
impact
speed
approv
obtain
regulatori
approv
may
especi
difficult
context
intern
trial
local
rule
may
differ
countri
countri
nation
regulatori
author
nra
may
insuffici
experi
seek
expert
opinion
delay
process
engag
nra
earli
stage
essenti
seek
opinion
propos
trial
design
captur
countri
requir
avail
trial
site
may
also
imped
progress
particularli
site
approv
work
gmo
vaccin
limit
lack
infrastructur
skill
personnel
capac
work
credibl
experienc
partner
help
minimis
delay
sever
clinic
trial
network
alreadi
exist
facilit
clinic
develop
pathogen
specif
minimis
bottleneck
overcom
bottleneck
find
clinic
trial
site
experienc
nra
act
credibl
author
essenti
earli
discuss
need
occur
tandem
develop
product
avoid
delay
process
map
tool
emphasis
import
ethic
regulatori
consider
throughout
entir
process
iter
workshop
continu
highlight
import
earli
engag
appropri
advic
input
shape
r
tool
provid
overview
signpost
organis
inform
sourc
mani
outbreak
vaccin
may
never
go
market
authoris
due
commerci
incent
manufactur
nevertheless
sever
stage
necessari
approv
must
obtain
order
proceed
develop
test
candid
regular
market
author
eu
vaccin
develop
must
provid
full
develop
dataset
preclin
clinic
trial
result
evid
clinic
safeti
efficaci
well
evalu
posit
benefitrisk
ratio
map
tool
highlight
discuss
tpp
uk
medicin
healthcar
product
regulatori
agenc
mhra
approach
time
anim
work
regul
anim
scientif
procedur
act
aspa
uk
govern
home
offic
licensur
must
provid
institut
person
project
level
use
gmo
vaccin
regul
separ
legisl
approv
must
given
health
safeti
execut
hse
carri
experiment
medicin
studi
immun
respons
human
health
research
author
hra
provid
ethic
approv
research
ethic
servic
re
project
nh
led
england
clinic
trial
authoris
cta
made
formal
applic
mhra
trialist
must
provid
inform
mode
action
natur
target
anim
model
studi
imp
dossier
preclin
toxicolog
data
human
mechanisticproof
concept
studi
though
regul
specif
uk
mani
countri
requir
similar
level
scrutini
case
lifethreaten
infect
conceiv
mani
prioriti
vaccin
develop
ultim
never
undergo
standard
clinic
trial
process
use
outbreak
situat
eual
circumst
imper
test
novel
vaccin
candid
well
characteris
anim
model
previous
appli
defenc
vaccin
due
limit
clinic
test
fda
anim
rule
may
provid
pathway
test
novel
vaccin
candid
outbreak
set
case
ebola
possibl
undertak
emerg
use
protocol
expedit
authoris
ensur
promis
vaccin
candid
deploy
human
use
justifi
major
interest
public
health
andor
therapeut
innov
gener
framework
could
appli
vaccin
r
broadli
establish
work
group
undertook
seri
meet
appli
process
map
three
case
studi
differ
vaccin
candid
develop
three
ukvn
prioriti
pathogen
mer
viral
vector
vaccin
zika
protein
subunitvlp
vaccin
fig
prokarium
vaxonella
plagu
vaccin
fig
case
studi
access
main
land
page
process
map
mer
select
sever
candid
later
stage
develop
includ
viral
vector
vaccin
candid
mer
viral
vector
approach
overcom
number
bottleneck
speed
develop
mainli
impact
preclin
develop
stage
overcom
delay
would
associ
masterse
bank
product
preformul
workin
vitro
vivo
lead
identif
antigen
identif
bottleneck
also
overcom
straightforward
select
spike
protein
major
extern
antigen
coronavirus
elicit
neutralis
antibodi
receptor
bind
domain
bottleneck
remain
relev
gener
tool
basic
understand
humanlivestock
host
immunolog
use
appropri
anim
challeng
model
camel
would
suitabl
place
facil
larg
model
three
main
bottleneck
clinic
develop
obtain
ethic
regulatori
approv
work
vaccin
classifi
gmo
viral
vector
platform
alter
genet
origin
form
avail
oversea
trial
site
bottleneck
identifi
appli
vaccin
develop
process
map
novel
zika
vaccin
time
ukvn
format
zika
littl
heard
modest
invest
potenti
emerg
viru
uk
research
fund
portfolio
work
ukvn
progress
zika
outbreak
unfold
funder
uk
intern
mobilis
increas
invest
ukvn
immedi
ad
zika
prioriti
pathogen
list
contribut
number
fund
stream
support
vaccin
r
appli
process
map
tool
emerg
pathogen
allow
visualis
signific
number
unknown
challeng
deal
littleknown
emerg
diseas
without
platform
approach
fig
earliest
preclin
discoveri
stage
pathogen
biolog
host
immunolog
rate
limit
particularli
identifi
region
viru
could
use
possibl
antigen
vitro
studi
deploy
vivo
challeng
model
also
rate
limit
gener
reagent
appropri
assay
need
establish
without
robust
set
assay
gener
antigen
earli
discoveri
phase
bottleneck
would
overcom
howev
identif
surrogatecorrel
protect
appropri
challeng
model
import
note
mani
vaccin
launch
without
establish
correl
protect
depend
licensur
sought
sever
diseas
outbreak
preclin
develop
due
novelti
vaccin
process
develop
assay
adjuvantis
formul
identifi
bottleneck
time
could
save
platform
technolog
use
vaccin
circumv
mani
step
process
develop
formul
clinic
develop
deploy
human
challeng
model
studi
respons
vaccin
studi
consid
ratelimit
must
note
case
emerg
experiment
licensur
strategi
might
establish
anim
challeng
data
seek
establish
safeti
data
phase
trial
expans
phase
trial
howev
demonstr
efficaci
one
endem
outbreak
situat
requir
earli
engag
nra
locat
suitabl
oversea
trial
site
potenti
ratelimit
plagu
vaccin
potenti
dual
applic
develop
path
could
collabor
govern
agenc
produc
antibioterror
vaccin
could
expand
develop
vaccin
endem
diseas
region
madagascar
dual
natur
affect
way
think
tpp
develop
path
mer
case
studi
plagu
vaccin
exploit
platform
technolog
prokarium
vaxonella
platform
thu
mani
bottleneck
particularli
preclin
develop
circumv
fig
main
bottleneck
clinic
phase
anim
rule
regul
necessari
follow
licensur
particular
pathogen
vaccin
approach
includ
qualiti
control
phase
ii
regulatori
requir
two
anim
model
fill
finish
phase
ii
safeti
studi
meet
requir
licensur
regul
case
studi
demonstr
use
process
map
vaccin
develop
use
platform
technolog
enabl
mani
develop
step
circumv
thu
overcom
ratelimit
step
could
vital
outbreak
situat
speed
develop
must
minimis
possibl
addit
featur
tool
also
present
work
complet
undertaken
better
understand
feasibl
challeng
develop
vaccin
major
ukvn
prioritis
pathogen
ukvn
member
agre
develop
new
vaccin
might
alway
appropri
respons
outbreak
set
particularli
candid
vaccin
earli
stage
present
signific
r
manufactur
challeng
thu
may
appropri
deploy
healthcar
intervent
manag
diseas
therapeut
antibodi
contain
procedur
prioritis
guid
address
technic
feasibl
creat
vaccin
togeth
public
health
valu
base
pathogen
sever
altern
vaccin
final
consider
time
scale
cost
develop
singl
criterion
address
avail
vaccin
candid
consid
stage
develop
exist
candid
includ
manufactur
consider
whether
vaccin
may
alreadi
stockpil
criteria
red
amber
green
statu
taken
togeth
enabl
decisionmak
suitabl
pursu
vaccin
r
outbreak
set
tool
repres
first
step
toward
understand
limit
factor
vaccin
develop
epidem
prepared
howev
still
sever
key
outstand
challeng
fulli
captur
first
sustain
fund
problem
partli
address
creation
coalit
epidem
prepared
innov
cepi
wwwcepinet
howev
improv
coordin
still
requir
industri
academia
govern
intern
organ
key
prioriti
polici
maker
futur
infrastructur
manufactur
capac
need
accur
assess
especi
fillfinish
capac
differ
vaccin
typesclass
addit
continu
research
requir
better
understand
correl
protect
appropri
anim
model
cours
discoveri
new
antigen
protect
emerg
pathogen
extraordinari
array
technolog
develop
potenti
chang
abil
respond
emerg
infecti
diseas
amongst
viral
vector
subunit
vaccin
forefront
howev
futur
innov
nucleic
acid
base
vaccin
horizon
current
dna
rna
vaccin
licens
human
use
yet
mileston
reach
mani
bottleneck
describ
current
elimin
meantim
funder
govern
polici
maker
must
focu
overcom
exist
bottleneck
identifi
employ
better
coordin
overcom
futur
epidem
threat
author
declar
conflict
interest
plagu
case
studi
summari
total
number
bottleneck
reduc
due
use
live
bacteri
vector
system
exploit
platform
technolog
plagu
antigen
alreadi
known
well
characteris
thu
mani
bottleneck
shift
clinic
develop
test
vaccin
candid
